Although agents available for controlling disease in mild ulcerative colitis (UC) are largely effective and well tolerated, many unmet needs exist in treating moderate to severe disease, and sizeable opportunity remains for therapies that target this patient population. Novel agents that can more effectively induce remission, achieve mucosal healing, and/or reduce corticosteroid use relative to the leading TNF-alpha inhibitors are areas of important need. With another cell adhesion molecule (CAM) inhibitor, an oral Janus-activated kinase (Jak) inhibitor, and an oral sphingosine-1-phosphate receptor (S1P-R) inhibitor in late-stage development for moderate to severe UC, the competition in the moderate to severe UC space is intensifying; novel agents will need to differentiate themselves in efficacy or safety in order to capture appreciable market share.
Ulcerative Colitis - Landscape & Forecast - Disease Landscape & Forecast
The ulcerative colitis (UC) therapy market is expected to grow steadily over the next decade. The entry of first-in-UC
Ulcerative Colitis | Disease Landscape and Forecast | G7 | 2020
The ulcerative colitis (UC) therapy market is expected to grow steadily over the next decade. The entry of first-in-UC oral therapies (e.g., Pfizer’s Xeljanz / Xeljanz XR) for moderate to severe di...
Ulcerative Colitis - Current Treatment - Detailed, Expanded Analysis: Treatment Algorithms - Claims Data Analysis (US) Dashboard
Ulcerative colitis (UC) is a chronic inte...